Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/233840
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invite to open peer review
Title

A bivalent B-cell epitope dendrimer peptide can confer long-lasting immunity in swine against foot-and-mouth disease

AuthorsCañas-Arranz, Rodrigo; Forner, Mar; Defaus, Sira; León, Patricia de CSIC ORCID; Torres, Elisa; Bustos, Maria José; Borrego, Belén CSIC ORCID; Sáiz, Margarita CSIC ORCID; Andreu, David; Sobrino Castelló, Francisco CSIC ORCID
KeywordsDendrimer peptide
FMDV
Protection
Swine
Vaccine
Issue Date20-Jan-2020
PublisherWiley-Blackwell
CitationTransboundary and Emerging Diseases 67: 1614- 1622 (2020)
AbstractFoot-and-mouth disease virus (FMDV) causes a widely extended contagious disease of livestock. We have previously reported that a synthetic dendrimeric peptide, termed BT(mal), consisting of two copies of a B-cell epitope [VP1(140–158)] linked through maleimide groups to a T-cell epitope [3A(21–35)] of FMDV, elicits potent B- and T-cell-specific responses and confers solid protection in pigs to type O FMDV challenge. Longer duration of the protective response and the possibility of inducing protection after a single dose are important requirements for an efficient FMD vaccine. Herein, we show that administration of two doses of BT(mal) elicited high levels of specific total IgGs and neutralizing antibodies that lasted 4–5 months after the peptide boost. Additionally, concomitant levels of IFN-γ-producing specific T cells were observed. Immunization with two doses of BT(mal) conferred a long-lasting reduced susceptibility to FMDV infection, up to 136 days (19/20 weeks) post-boost. Remarkably, a similar duration of the protective response was achieved by a single dose of BT(mal). The effect on the BT(mal) vaccine of RNA transcripts derived from non-coding regions in the FMDV genome, known to enhance the immune response and protection induced by a conventional inactivated vaccine, was also analysed. The contribution of our results to the development of FMD dendrimeric vaccines is discussed.
Publisher version (URL)http://dx.doi.org/10.1111/tbed.13497
URIhttp://hdl.handle.net/10261/233840
DOI10.1111/tbed.13497
Identifiersdoi: 10.1111/tbed.13497
issn: 1865-1682
Appears in Collections:(CBM) Artículos




Files in This Item:
File Description SizeFormat
SobrinoF_ABivalentB-cell.pdf967,6 kBAdobe PDFThumbnail
View/Open
Show full item record

CORE Recommender

SCOPUSTM   
Citations

9
checked on May 23, 2024

WEB OF SCIENCETM
Citations

9
checked on Feb 20, 2024

Page view(s)

84
checked on May 29, 2024

Download(s)

198
checked on May 29, 2024

Google ScholarTM

Check

Altmetric

Altmetric


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.